These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 5921331)

  • 1. Deferoxamine and diethylenetriaminepentaacetic acid (DTPA) in thalassemia.
    McDonald R
    J Pediatr; 1966 Oct; 69(4):563-71. PubMed ID: 5921331
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Thalassemia major: a problem of iron overload.
    Stockman JA; Oski FA
    Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathogenesis and management of iron overload in thalassemia.
    Hershko C
    Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456
    [No Abstract]   [Full Text] [Related]  

  • 6. Chelation therapy for the treatment of thalassemia.
    Graziano JH; Cerami A
    Semin Hematol; 1977 Jan; 14(1):127-34. PubMed ID: 318766
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

  • 8. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).
    Pippard MJ; Jackson MJ; Hoffman K; Petrou M; Modell CB
    Scand J Haematol; 1986 May; 36(5):466-72. PubMed ID: 3738427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 14. [Desferrioxamine-B in the diagnosis of hemosiderotic states and in the therapy of thalassemia. Apropos of 2 cases].
    De Luca G; Faelli U; Petrussa I
    Minerva Pediatr; 1966 Oct; 18(32):1920-5. PubMed ID: 5993655
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute iron poisoning in children: role of chelating agents.
    Barr DG; Fraser DK
    Br Med J; 1968 Mar; 1(5594):737-41. PubMed ID: 5641439
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron loading and thalassemia--experimental successes and practical realities.
    Weatherall DJ; Pippard MJ; Callender ST
    N Engl J Med; 1977 Aug; 297(8):445-6. PubMed ID: 560628
    [No Abstract]   [Full Text] [Related]  

  • 17. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 18. CHELATING AGENTS IN THE DIAGNOSIS AND TREATMENT OF IRON OVERLOAD IN THALASSEMIA.
    SMITH RS
    Ann N Y Acad Sci; 1964 Oct; 119():776-88. PubMed ID: 14219457
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.